Charles River Laboratories International, Inc. (CRL) · Nov 4, 2026 · Earnings

Charles River earnings beat as DSA demand lifts guidance

Beat — Adj. EPS $3.09 vs ~$2.97 consensus; revenue $982.7M vs ~$960.4M

Charles River earnings beat revenue and adjusted EPS expectations, with DSA strength lifting organic growth and 2026 guidance.

Charles River is in an early recovery phase for outsourced biopharma research, reshaping its portfolio around higher-value discovery, safety assessment, and manufacturing services after divesting CDMO and Cell Solutions assets. The setup was already improving: second-quarter organic growth had turned slightly positive, and September’s Investor Day pointed to better demand and long-term margin expansion.

This was a genuine quarterly beat, not just a tax-driven headline. Revenue reached $982.7 million versus a published consensus of roughly $960 million, while adjusted diluted EPS was $3.09 versus roughly $2.97. The bigger signal is organic revenue growth of 4.7%, well above the prior full-year target range of 0.0% to 1.0%. Revenue was still down 2.2% reported because the May divestitures removed businesses, but the continuing operations were growing faster than expected.

MetricQ3 2026Q3 2025Consensus / Prior guidance
Revenue (Financial Highlights)$982.7M (+4.7% organic)$1,004.9M~$960.4M consensus
Diluted EPS, non-GAAP (Earnings reconciliation)$3.09 (+27.2%)$2.43~$2.97 consensus
Non-GAAP operating margin (Segment results)23.0%19.7%—
2026 organic revenue growth (Guidance)At least +1.5%—0.0%–1.0% prior
2026 non-GAAP EPS (Guidance)$11.35–$11.55—$11.15–$11.45 prior

DSA is now the main engine of the recovery. Discovery and Safety Assessment delivered 5.9% organic growth and lifted its non-GAAP operating margin to 26.8% from 25.4%. Management also pointed to stronger bookings and proposals, which matters more than the reported revenue decline because it supports future workload conversion.

The earnings quality is better than GAAP EPS suggests, but not clean. GAAP EPS benefited from a $245.6 million, or $5.06 per-share, reversal of acquired tax reserves; that is not operating momentum. The adjusted result still improved 27.2% year over year, helped by margin expansion, DSA volume, and a lower tax rate. Manufacturing’s organic growth was strong at 7.4%, while RMS remained the weak spot with organic revenue down 0.6% and adjusted margin falling to 24.4% from 25.0%.

Guidance moved clearly above the prior operating baseline, though part of the upgrade was already foreshadowed. The company raised its organic revenue floor to at least 1.5% and its adjusted EPS range to $11.35–$11.55, after saying at Investor Day that results were tracking toward the upper end of the earlier range. That makes the direction partly known, but the quarter’s magnitude and the new organic-growth floor are fresh evidence that demand is improving faster than the August outlook assumed. 〔0〕

Bottom line: Charles River is showing the operating recovery investors were waiting for, led by DSA and supported by manufacturing strength. The tax benefit flatters GAAP results and RMS is still soft, but the core quarter beat expectations and pushed the business story meaningfully forward.

What to watch next

Q4 results and 2027 outlook

Original filing on SEC EDGAR

More Charles River Laboratories International, Inc. news

Charles River earnings beat as DSA demand lifts guidance | CRL Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.